Medical Condition News

RSS

Novartis submits JOULFERON MAA to the EMEA

Human Genome Sciences, Inc. today announced that Novartis has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) for approval to market JOULFERON® (albinterferon alfa-2b, known in the United States as ZALBIN™) for the treatment of chronic hepatitis C. In November 2009, HGS submitted a Biologics License Application (BLA) for ZALBIN to the FDA in the United States.

15 Dec 2009

Lytix Biopharma AS receives approval to commence Phase I clinical trials of Oncopore

The Norwegian pharmaceutical company Lytix Biopharma AS today announced approvals from the Norwegian Medicines Agency (”Statens legemiddelverk”) and the Swedish Medical Products Agency (”Läkemedelverket”) to commence Phase I clinical trials of OncoporeTM (LTX-315) for the treatment of cancer.

15 Dec 2009

Jazz Pharmaceuticals announces submission of JZP-6 NDA for treatment of fibromyalgia

Jazz Pharmaceuticals, Inc. announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for JZP-6 (sodium oxybate oral solution) for the treatment of fibromyalgia.

15 Dec 2009

New technique may help diagnose treatments for Alzheimer's, diabetes and cancer

Chemists and biologists from the University of Bath have developed a new technique that could be used to diagnose and develop treatments for age-related conditions like Alzheimer's disease, diabetes and cancer.

15 Dec 2009

Cerebrospinal fluid signature and PiB imaging help predict Alzheimer's disease

Early Alzheimer's disease detected by a compound that binds to brain plaques appears likely to progress into symptomatic Alzheimer's disease with dementia, according to a report in the December issue of Archives of Neurology, one of the JAMA/Archives journals.

15 Dec 2009

Risks and benefits of CT scans

Doses of radiation from commonly performed computed tomography (CT) scans vary widely, appear higher than generally believed and may contribute to an estimated tens of thousands of future cancer cases, according to two reports in the December 14/28 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

15 Dec 2009

Mutant ATPase blocks autophagy partway and causes multi-tissue degenerative disease

It's important to finish what you start, say Jeong-Sun Ju and researchers from Washington University School of Medicine, St. Louis. In the December 14, 2009 issue of the Journal of Cell Biology (www.jcb.org), Ju et al. reveal how a mutant ATPase blocks autophagy partway through to cause a multi-tissue degenerative disease.

15 Dec 2009

Nanoprobes deliver drugs directly to the right tumor cellular compartments

Tiny nanoprobes have shown to be effective in delivering cancer drugs more directly to tumor cells - mitigating the damage to nearby healthy cells - and Purdue University research has shown that the nanoprobes are getting the drugs to right cellular compartments.

15 Dec 2009

Cancer patients with dementia have lower survival rate than patients with cancer alone, says study

A new study published by researchers from the University of Georgia and the Moffitt Cancer Center in Tampa, Fla., has found that cancer patients with dementia have a dramatically lower survival rate than patients with cancer alone, even after controlling for factors such as age, tumor type and tumor stage.

15 Dec 2009

Findings suggest variations in accelerated aging disorders

UT Southwestern Medical Center researchers have provided the most extensive account to date of the unique observable characteristics seen in patients with an extremely rare premature aging syndrome.

15 Dec 2009

Study to determine link between insulin glargine and cancer

Type 2 diabetes and obesity are linked to an increased risk of certain cancers. Recently published studies suggested that insulin glargine (a synthetic insulin preparation marketed under the trade name Lantus), may be associated with a higher risk of certain cancers than other insulins or oral glucose lowering medications. However, these studies were unable to control for important factors such as obesity that may have driven the association.

15 Dec 2009

Enrolment for pivotal Phase II/III trial of C-Cure completed ahead of schedule

Cardio3 BioSciences, a leading Belgian biotechnology company specialising in cell-based therapies for the treatment of cardiovascular diseases, announced today that it has completed, two months ahead of schedule, enrolment in the first stage of its pivotal Phase II/III trial of C-Cure, a unique stem cell therapy for heart failure.

15 Dec 2009

Intensive medical therapy may benefit patients with asymptomatic plaque buildup

Intensive medical therapy, including aggressive control of blood pressure and cholesterol levels, for patients with asymptomatic plaque buildup in their carotid arteries (which supply blood to the brain) appears to be associated with reduced rates of cardiovascular events and reduced risk of microemboli (microscopic-sized blood clots) in the brain arteries, according to a report posted online today that will appear in the February 2010 print issue of Archives of Neurology, one of the JAMA/Archives journals.

15 Dec 2009

People with periodontal disease are at high risk for diabetes, survey finds

The study, led by Dr. Shiela Strauss, Associate Professor of Nursing and Co-Director of the Statistics and Data Management Core for NYU's Colleges of Dentistry and Nursing, examined data from 2,923 adult participants in the 2003-2004 National Health and Nutrition Examination Survey who had not been diagnosed with diabetes.

15 Dec 2009

Florida doctor performs new, effective treatment for sinusitis

Local physician William Laskowski, MD has become the first doctor in Florida to perform an effective new treatment for sinusitis called FinESS® Sinus Treatment in an office setting. FinESS® (Entellus Medical, Maple Grove, MN) is a balloon sinuplasty option that is less-invasive than traditional sinus surgery and breaks the cycle of chronic or recurrent sinusitis with immediate relief and lasting results.

15 Dec 2009

Retrospective study demonstrates new survival data for patients with myelofibrosis

A recent study, published in the December issue of Mayo Clinic Proceedings, demonstrates new survival data for the blood disorder myelofibrosis. This retrospective study is the largest ever conducted in young patients with primary myelofibrosis.

15 Dec 2009

New study to help researchers develop highly effective drug for MLL

A new study could point the way to the development of better drugs to fight a deadly form of childhood leukemia called mixed-lineage leukemia (MLL).

15 Dec 2009

Findings raise new hope for asthma and chronic obstructive pulmonary disease

A new study involving data from more than 20,000 individuals has uncovered several DNA sequences linked to impaired pulmonary function. The research, an analysis that combined the results of several smaller studies, provides insight into the mechanisms involved in reaching full lung capacity.

15 Dec 2009

INS cites FDA-approved Totect antidote for anthracycline extravasations

The third edition of Infusion Nursing: An Evidence-Based Approach, published by the Infusion Nurses Society (INS), includes Totect(®), the only FDA-approved treatment for anthracycline extravasation. Anthracyclines are a group of chemotherapy medications including daunorubicin, doxorubicin, idarubicin and epirubicin that have been used in the treatment of various types of cancer since the early 1970s.

15 Dec 2009

Scientists identify protein switch that helps prevent liver cancer

A team of scientists from the UC San Diego School of Medicine and Osaka University in Japan have identified a protein switch that helps prevent liver damage, including inflammation, fibrosis and cancer. The findings suggest that a better understanding of how the protein, TAK1, works could lead to new insights into the development of liver disease and cancer.

15 Dec 2009